

## Pharmacy Formulary Updates for November 2019

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in November 2019:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
<b>buprenorphine/naloxone films</b>	T2
<b>Copaxone</b>	T2;QL;SP
<b>Cutaquig</b>	MB;PA
<b>Kanjinti</b>	MB
<b>Mayzent</b>	T2;QL;SP
<b>Mvasi</b>	MB
<b>Nayzilam</b>	T3;PA;QL
<b>Nubeqa</b>	NC;SP
<b>Rinvoq</b>	T2;PA;QL;SP
<b>Sucraid</b>	T3
<b>Symjepi</b>	NC;QL
<b>Tosymra</b>	NC;QL
<b>Turalio</b>	T2;PA
<b>Xpovio</b>	T2;PA

**Key:**

<b>MB:</b> Medical Benefit	<b>QL:</b> Quantity Limitation
<b>NC:</b> Not covered	<b>SP:</b> Specialty Pharmacy - provided through CVS/specialty
<b>NTM:</b> New-to-market	<b>ST:</b> Step Therapy
<b>PA:</b> Prior Authorization	